SCHEMBL15280746

SCHEMBL15280746

CNc1ncc2cc(OC)c(C)nc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.37
▸ PRNP P04156 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ P2RX3 P56373 1/20 0.37
▸ P2RX2 Q9UBL9 1/20 0.37
▸ RAF1 P04049 3/20 0.36
▸ MAPK8 P45983 2/20 0.36
▸ KRAS P01116 2/20 0.36
▸ BRAF P15056 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ MAPK14 Q16539 2/20 0.36
▸ MAPK13 O15264 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ FYN P06241 1/20 0.36
▸ ARAF P10398 1/20 0.36
▸ SRC P12931 1/20 0.36
▸ EPHA2 P29317 1/20 0.36
▸ CSK P41240 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24457818 0.78 RAF1 (0.39) ALDH1A1MAPTP2RX3P2RX2RAF1
SCHEMBL15263527 0.77 RAF1 (0.38) ALDH1A1RAF1MAPK8KRASBRAF
SCHEMBL29699267 0.77 RAF1 (0.38) ALDH1A1RAF1MAPK8KRASBRAF
SCHEMBL29427237 0.77 RAF1 (0.38) RAF1MAPK8KRASBRAFKDR
SCHEMBL15263808 0.77 RAF1 (0.38) RAF1MAPK8KRASBRAFKDR
SCHEMBL1942842 0.75 ALDH1A1 (0.59) ALDH1A1MAPTKDM4ESMN1; SMN2PDGFRB
SCHEMBL15280809 0.74 MEN1 (0.41) ALDH1A1PRNPMAPTNPSR1RXFP1
SCHEMBL27103117 0.73 MAPK8 (0.38) P2RX3P2RX2MAPK8LRRK2
SCHEMBL22612761 0.70 RAF1 (0.34) RAF1MAPK8KRASBRAFKDR
SCHEMBL27103170 0.68 RAF1 (0.33) RAF1MAPK8KRASBRAFKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334267-B2 RAF inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2016-05-10 — — US disclosed
US-20150119392-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-30 — — US disclosed
US-8741911-B2 Raf inhibitor compounds ELI LILLY AND COMPANY (US) 2014-06-03 — — US disclosed
US-20130252977-A1 Raf Inhibitor Compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2013-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252977-A1 Raf Inhibitor Compounds BRAF, RAF1, ARAF ALDH1A1 1870/4885PRNP 3973/4885MAPT 3515/4885
US-20150119392-A1 RAF INHIBITOR COMPOUNDS BRAF, RAF1, NRAS ALDH1A1 1552/4885PRNP 4105/4885MAPT 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback